Novo Nordisk A/S (NYSE:NVO)

107.83
Delayed Data
As of 3:59pm ET
 +0.08 / +0.07%
Today’s Change
78.71
Today|||52-Week Range
122.16
-3.72%
Year-to-Date
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck, and Glaxo
May 20 / Zacks.com - Paid Partner Content
Lilly's (LLY) Diabetes Treatment Tirzepatide Gets FDA Nod
May 16 / Zacks.com - Paid Partner Content
Is Perrigo a Buy After Reporting Q1 Earnings?
May 20 / StockNews.com - Paid Partner Content
How Novo Nordisk Will Protect Insulin Sales
May 12 / MotleyFool.com - Paid Partner Content
4 Large Drug Stocks to Watch as the Industry Recovers
May 19 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close107.75
Today’s open107.95
Day’s range107.29 - 108.43
Volume823,702
Average volume (3 months)1,505,739
Market cap$187.3B
Data as of 3:59pm ET, 05/23/2022

Growth & Valuation

Earnings growth (last year)+19.70%
Earnings growth (this year)+7.43%
Earnings growth (next 5 years)+14.39%
Revenue growth (last year)+15.27%
P/E ratio34.9
Price/Sales11.53
Price/Book22.69

Competitors

 Today’s
change
Today’s
% change
NVSNovartis+1.30+1.45%
AZNAstraZeneca+0.20+0.30%
BMYBristol-Myers Squibb+0.50+0.66%
MRKMerck+0.30+0.32%
Data as of 5:52pm ET, 05/23/2022

Financials

Next reporting dateAugust 4, 2022
EPS forecast (this quarter)$0.83
Annual revenue (last year)$22.4B
Annual profit (last year)$7.6B
Net profit margin33.92%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
No executives to display
Corporate headquarters
Bagsværd, Capital Region

Forecasts